🔎 Trials Near Me

Почетна › Рак (све врсте) › Kalifornija › Irvine

Kliničke studije za Рак (све врсте) u gradu Irvine, CA

18 studija za Рак (све врсте) traži učesnike na lokacijama u gradu Irvine i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Тражи се учесникФаза 3
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • Kaiser Permanente-Irvine, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06580314

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Тражи се учесникФаза 2
  • City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07169851

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

Тражи се учесникФаза 3
  • University of California, Irvine, Irvine
Узраст од 18 до 71 · Оба пола · Ажурирано 30. 10. 2026. · NCT07504458

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Тражи се учесникФаза 3
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT04928846

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

Тражи се учесникФаза 1
  • University of California Irvine, Irvine
  • Lennar Foundation Cancer Center, Irvine
Узраст 18 и старији · Мушкарци · Ажурирано 27. 10. 2026. · NCT05997615

A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

Тражи се учесникФаза 1
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 279067, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 20. 10. 2026. · NCT07409246

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Тражи се учесникФаза 1/2
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277911, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT06892522

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Тражи се учесникФаза 2/3
  • Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • UCI Health - Irvine, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06989437

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Тражи се учесникФаза 2/3
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 284734, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT07005102

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Тражи се учесникФаза 2/3
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT07155187

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Тражи се учесникФаза 3
  • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 281396, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 23. 9. 2026. · NCT07365241

Statins to Prevent Cancer Associated Blood Clots

Тражи се учесникФаза 4
  • City of Hope, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07303816

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Тражи се учесникФаза 3
  • Hoag Hospital Center, Irvine
  • Hoag Hospital Irvine, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06072612

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

Тражи се учесник
  • UCI Health Susan Samueli Integrative Health Institute, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 10. 7. 2026. · NCT07581080

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Тражи се учесникОпсервациона студија
  • Massive Bio SYNERGY-AI site, Irvine
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Тражи се учесникФаза 1
  • UC Irvine, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2025. · NCT05808634

A Biobehavioral Intervention for Latino/Hispanic Young Adults with Cancer

Тражи се учесник
  • University of California, Irvine, Irvine
Узраст од 18 до 39 · Мушкарци · Ажурирано 25. 3. 2025. · NCT06338475

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Тражи се учесник
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Узраст 18 и старији · Оба пола · Ажурирано 27. 11. 2024. · NCT03860883

Studije za Рак (све врсте) u drugim gradovima

Ostale studije u gradu Irvine

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.